A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the ...

Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo has become the first to be approved by the FDA for use in pregnancy to protect newborns and infants from lower respiratory tract disease ...

Pfizer has reported top-line results from the Phase III RENOIR clinical trial of its respiratory syncytial virus (RSV) vaccine, ABRYSVO, for RSV-linked lower respiratory tract disease (LRTD).

Pfizer’s (NYSE:PFE) respiratory syncytial virus (RSV) vaccine Abrysvo was well-tolerated and generated strong neutralizing ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on ...

Drug company Pfizer is seeking to expand the approval of its respiratory syncytial virus (RSV) vaccine to include adults over the age of 18.

The respiratory syncytial virus (RSV) vaccines, Abrysvo, manufactured by Pfizer Inc. (PFE), and Arexvy, manufactured by GlaxoSmithKline Biologicals, were approved in May 2023. Postmarketing ...

Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized ... In a earnings report Tuesday, Pfizer said sales of its vaccine Abrysvo fell 62% year over year ...